

# MEDICAL POLICY



<b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b>	<b>EFFECTIVE DATE: 11/19/99</b>
<b>POLICY NUMBER: 2.01.07</b>	<b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b>
<b>CATEGORY: Technology Assessment</b>	<b>PAGE: 1 OF: 15</b>

- *If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.*
- *If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.*
- *If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.*

## POLICY STATEMENT:

### I. Topical hyperbaric oxygen therapy

Based on our criteria and review of the peer-reviewed literature, *topical* hyperbaric oxygen therapy has not been medically proven to be effective and is considered **investigational**.

### II. Systemic hyperbaric oxygen therapy

A. Based on our criteria and review of the peer-reviewed literature, *systemic* hyperbaric oxygen therapy in a pressurized chamber has been medically proven to be effective and therefore **medically appropriate** for the following indications (*refer to Policy Guideline V for condition specific recommendations*):

1. Air or Gas embolism, acute;
2. Arterial Inefficiencies: Enhancement of Healing in Selected Wounds in patients with *Diabetic* non-healing wounds of the lower extremities in patients and have:
  - i. Type I or type II diabetes and a lower extremity wound due to diabetes and have:
  - ii. A wound classified as Wagner grade 3 or higher (Grade 2: ulcer penetrates to tendon, bone or joint; Grade 3: lesion has penetrated deeper than grade 2 and there is abscess, osteomyelitis, pyarthrosis, plantar space abscess, or infection of the tendon and tendon sheaths; Grade 4: gangrene of the forefoot; and
  - iii. have no measurable signs of healing after 30 days of an adequate course of standard wound therapy; which includes the following:
    - 1) assessment of vascular status and correction of any vascular problems in the affected limb if possible;
    - 2) optimization of nutritional status;
    - 3) optimization of glucose control;
    - 4) debridement by any means to remove devitalized tissue;
    - 5) maintenance of clean, moist bed of granulation tissue with appropriate moist dressings;
    - 6) appropriate off-loading; and
    - 7) necessary treatment to resolve any infection that might be present
3. Carbon monoxide poisoning, acute;
4. Cerebral edema, acute;
5. Compromised Grafts and Flaps (not for primary management of these wounds);
6. Crush injury with acute traumatic ischemia and suturing of severed limbs;
7. Cyanide poisoning, acute;
8. Decompression sickness;
9. Gas/wet gangrene (e.g., clostridial myonecrosis);
10. Necrotizing Soft Tissue Infections: based on location and/or organism type and/or particular host immunologic and vascular risk factors causing hypoxia resulting in necrosis.
11. Osteomyelitis, acute, refractory (has not responded to standard medical and surgical management techniques);

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 2 OF: 15</b></p>
--	--

12. Osteomyelitis, chronic refractory (has persisted for at least 6 weeks or recurred after appropriate interventions - surgical debridement and at least one appropriate course of parenteral antibiotics - have been performed);
  13. Pre- and post-treatment for patients undergoing dental surgery (non-implant related) of an irradiated jaw;
  14. Profound anemia with exceptional blood loss: only when blood transfusion is impossible or must be delayed;
  15. Radiation necrosis osteoradionecrosis (ORN)/bony necrosis and soft tissue radiation necrosis, e.g., radiation enteritis, cystitis, proctitis); or
  16. Refractory mycosis: mucormycosis, actinomycosis, canidiobolus coronato
- B. Based on our criteria and review of the peer-reviewed literature, *systemic* hyperbaric oxygen therapy in a pressurized chamber has not been medically proven to be effective and is considered **investigational** for all other indications including, but not limited to, the following indications:
1. Acute ischemic stroke;
  2. Amyotrophic Lateral Sclerosis;
  3. Arterial peripheral insufficiency, acute;
  4. Autism spectrum disorders;
  5. Bell's palsy;
  6. Bone grafts;
  7. Breast cancer, locally advanced, as pretreatment for patients undergoing chemotherapy;
  8. Brown recluse spider bites;
  9. Carbon tetrachloride poisoning, acute;
  10. Cardiopulmonary bypass, as pretreatment;
  11. Cerebral palsy;
  12. Cerebrovascular disease, acute (thrombotic or embolic) or chronic;
  13. Chronic, non-healing wounds;
  14. Complex regional pain syndrome;
  15. Uncompromised skin grafts or flaps;
  16. Fibromyalgia syndrome;
  17. Fracture healing;
  18. Frostbite;
  19. Head injury, traumatic (including traumatic brain injury);
  20. Hearing loss (e.g., idiopathic sudden sensorineural hearing loss) and tinnitus;
  21. Hydrogen sulfide poisoning;
  22. Inflammatory bowel disease (Crohn's disease, ulcerative colitis);
  23. Interstitial cystitis;
  24. Intra-abdominal and intracranial abscesses;
  25. In vitro fertilization;
  26. Lepromatous leprosy;
  27. Malignant otitis externa;
  28. Meningitis;
  29. Migraine;
  30. Myocardial infarction and acute coronary syndrome (acute myocardial infarction and unstable angina);
  31. Multiple sclerosis;
  32. Muscle soreness, delayed onset;
  33. Prevention of coronary restenosis;
  34. Pseudomembranous colitis (antimicrobial agent-induced colitis);
  35. Pyoderma gangrenosum;

<b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b>  <b>POLICY NUMBER: 2.01.07</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 11/19/99</b> <b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b>  <b>PAGE: 3 OF: 15</b>
---	---

- 36. Radiation myelitis;
- 37. Radiation therapy, for the purpose of tumor sensitization;
- 38. Retinal artery insufficiency, acute;
- 39. Retinal detachment;
- 40. Retinopathy, adjunct to scleral buckling procedures in patients with sickle cell peripheral retinopathy;
- 41. Sickle cell crisis and/or hematuria;
- 42. Soft tissue injury;
- 43. Spinal cord injury;
- 44. Thermal burns, acute.

**POLICY GUIDELINES:**

- I. HBOT should not be a replacement for successful standard therapeutic measures. Documentation in the medical record should support the specific condition being treated with HBOT and the medical necessity of such treatment. The following information must be documented, as applicable, to the specific medical condition:
  - A. Initial assessment and medical history detailing the condition requiring HBOT and a physical exam. The history should list prior treatments including antibiotic therapy and surgical interventions.
  - B. Current adjunctive treatment that includes treatment-type and its effectiveness.
  - C. Established HBOT goals.
  - D. HBOT session records describing physical findings and treatment rendered (including ascent time, descent time, total compression time, oxygen dose, pressurization level, documentation of attendance, and a recording of events).
  - E. Effect of treatment upon established HBOT goals.
  - F. When applicable, advanced diabetic foot ulcers may require photos to avoid overuse of HBOT when the foot is not salvageable. For a Wagner 5 (or Grade D) with complete gangrene of foot, once the heel is necrotic, the patient will likely not respond to HBOT treatments.
- II. HBOT treatments of diabetic wounds of the lower extremities should be discontinued when either the patient heals, is unable to tolerate treatment, or fails to improve. Documentation must include an assessment of wound healing progress, changes in the wound condition including the precise wound length, width, and depth measurements, presence of granulation and necrotic tissue, and concurrent measures being addressed relative to wound therapy. Weekly wound measurements should be performed to document progress in wound healing. A steady decrease in wound volume should be noted from week to week.
- III. Continued treatment with HBOT is not covered if measurable signs of healing have not been demonstrated within any 30-day period of treatment. Most patients should NOT require more than 40 treatments. If they do not respond to 40 treatments, they will likely not-respond to 60 or 80 or 120 treatments.
- IV. Below are specific recommendations on the utilization of HBOT based upon published, peer-reviewed literature.

<b><u>Condition</u></b>	<b><u>Pressure (ATA*)</u></b>	<b><u>Patient Selection Criteria</u></b>	<b><u>Duration, Frequency and/or Number of Treatments</u></b>	<b><u>Utilization review</u></b>
Air or Gas embolism, acute	High to low pressure mixed gases	Gases in the vasculature sufficient enough to interfere with the function of an organ and results in ischemia to the affected areas.	Treatment is typically 1-2 treatments but occasionally up to 5-10; treatment continues until no additional improvement is seen.	After 10 treatments
Anemia, severe	2.0-3.0 ATA	When blood transfusion is impossible or must be delayed.	Treatments of up to 3 or 4 hours, three to four times a day. Treatment can continue with taper of time and frequency until red	Daily

<b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b>  <b>POLICY NUMBER: 2.01.07</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 11/19/99</b> <b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b>  <b>PAGE: 4 OF: 15</b>
---	---

<u>Condition</u>	<u>Pressure (ATA*)</u>	<u>Patient Selection Criteria</u>	<u>Duration, Frequency and/or Number of Treatments</u>	<u>Utilization review</u>
			blood cells have been satisfactorily replaced by patient regeneration or the patient can undergo transfusion.	
Arterial Inefficiencies: non-healing <i>diabetic wounds</i> of the lower extremities	2.0-3.0 ATA	Wagner grade 3 or higher and failure of standard wound therapy for at least 30 consecutive days.	90 minute treatments, 5 days per week are performed in conjunction with continuing standard wound care; may last for 30-40 treatments.	After 40 treatments
Carbon monoxide poisoning, acute	2.5-3.0 ATA	Within 6 hours of patient removal from the carbon monoxide contaminated environment.	One treatment; if patient has persistent neurologic dysfunction after the initial treatment further treatment can occur within 6-8 hours and can be continued once or twice daily until there is no additional improvement in cognitive function.	After 5 treatments
Compromised Grafts and Flaps	2.0-2.5 ATA	In tissue compromised by irradiation or in other cases where there is decreased perfusion (vascular compromise) or hypoxia, HBO2T has been shown to be extremely useful in flap salvage. This indication is not for primary management of wounds for normal, uncompromised skin grafts or flaps.	90-120 minutes. It is not unusual to receive treatments twice a day. When the graft or flap appears stable, treatments are reduced to daily. Should a graft or flap fail, HBO therapy may be used to prepare the already compromised recipient site for a new graft or flap. It does not apply to the initial preparation of the body site for a graft.	After 40 treatments
Crush injury	2.0-2.4 ATA	In conjunction with standard therapeutic measures when loss of function, limb or life is threatened and tissue oxygen tension is below 30 mmHg.	Three 1.5 hours treatments per day for 2 days, then twice a day for 2 days, and once daily for 2 days	After 20 treatments
Cyanide poisoning, acute	2.5-3.0 ATA	As an adjunct to infusion of sodium nitrite.	One treatment of 120 minutes.	

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 5 OF: 15</b></p>
--	--

<u>Condition</u>	<u>Pressure (ATA*)</u>	<u>Patient Selection Criteria</u>	<u>Duration, Frequency and/or Number of Treatments</u>	<u>Utilization review</u>
Decompression sickness	2.0-5.0 ATA	Gas bubbles in the tissue or blood in volumes sufficient enough to interfere with the function of an organ or cause alteration in sensation.	One treatment of 1.5- 14 hours duration; if patients has residual defects after the initial the initial treatment they should receive additional treatments until clinical stability is achieved; generally no more than 5-10 treatments.	After 10 treatments
Gas gangrene (e.g., clostridial myonecrosis)	3.0 ATA	Positive gram stained smear or culture from tissue fluids, tissue gas visualization on x-ray, severe and sudden pain, skin changes, and edema.	Three 90-minute treatments during the first 24 hours and then two treatments per day for the next 2-5 days.	After 10 treatments
Necrotizing Soft Tissue Infections:	2.0-2.5 ATA	Adjunctive therapy only in patients where morbidity and mortality are expected to be high despite aggressive standard treatment.	Twice daily for 90 to 120 minutes until condition is stabilized, then once daily.	After 30 treatments
Osteomyelitis, chronic, refractory	2.0-2.5 ATA	HBOT should not be used as a primary treatment for osteo. Only after surgical debridement and at least one 6 week appropriate course of parenteral anti-biotics have been performed should HBOT be considered.	Daily treatment for 90-120 minutes and can be continued for 4-6 weeks for patients who respond to initial treatment with antibiotics, surgical debridement and hyperbaric oxygen therapy.	After 30-40 sessions
Osteoradionecr-osis	2.0-2.5 ATA	As adjunctive treatment in the preoperative and postoperative management of the patient.	30 treatments followed by only minor bony debridement. If response is adequate, an additional 10 treatments can be given. If patients are not responding they are considered stage II and receive more extensive surgical debridement then 10 additional treatments. Stage III patients receive 30 treatments followed by mandibular segmental resection and then 10 additional treatments.	After 10-30 treatments

<b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b>  <b>POLICY NUMBER: 2.01.07</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 11/19/99</b> <b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b>  <b>PAGE: 6 OF: 15</b>
---	---

<u>Condition</u>	<u>Pressure (ATA*)</u>	<u>Patient Selection Criteria</u>	<u>Duration, Frequency and/or Number of Treatments</u>	<u>Utilization review</u>
Osteoradionecrosis, mandibular (i.e. Marx Protocol for ORN and Tooth Extraction)	2.0-2.5 ATA	Evidence of overt fracture or bony resorption. Marx Protocol: Pre-and post-treatment for patients undergoing dental surgery (non-implant related) of an irradiated jaw.	Initial treatment for stage I patients is 30 treatments. If response is adequate 10 additional treatments can be provided. Non-responders are considered stage II and receive more extensive surgical debridement followed by 10 additional treatments. Patients with stage III disease can receive up to 30 treatments followed by mandibular segmental resection and then an additional 10 treatments.	After 10-30 treatments
Refractory mycosis (e.g., actinomycosis, mucormycosis)	2.0-2.5 ATA	In conjunction with standard treatment when the disease process is refractory to antibiotics and surgical treatment.	One to two times daily for 90-120 minutes; treatment can continue for up to 40-80 treatments.	After 10-30 treatments

\*1 ATA (atmospheres absolute) = pressure of 760 mmHg, 14.7 psi, 760 torr, or 33 ft of seawater.

Information relating to the frequency of treatment and other treatment specifics can also be found at the web site of the Undersea & Hyperbaric Medical Society (UHMS) [<https://www.uhms.org/resources/hbo-indications.html>].

- VI. It is recommended the Centers for Medicare and Medicaid Services (CMS) criteria for coverage be utilized in determining appropriate practitioners to render hyperbaric oxygen therapy. The CMS criteria states:
- A. Qualified non-physician practitioners (NPPs) may supervise hyperbaric oxygen therapy services, if such service is included within their State scope of practice, if their required supervision or collaborative agreement is with a physician qualified to provide HBOT services, and if the NPP meets the educational requirements identified within the coverage article.
  - B. Physicians supervising hyperbaric oxygen therapy should be certified in Undersea and Hyperbaric Medicine by the American Board of Emergency Medicine (ABEM) or the American Board of Preventive Medicine (APBM) or the American Osteopathic Conjoint Committee of Undersea and Hyperbaric Medicine (AOCUHM); or must have completed a minimum 40-hour training experience in a program such as one approved by the American College of Hyperbaric Medicine or the Undersea and Hyperbaric Medical Society.
  - C. Advanced Cardiac Life Support (ACLS) training and certification of supervising physicians (and NPPs) is required in physician offices and off-campus hospital sites; and in on-campus provider-based departments for which provider-response time to the chamber can be expected to exceed five minutes.
  - D. HBO therapy rendered within a hospital outpatient department is considered “incident to” a physician’s or qualified NPP’s services and requires physician supervision. The physician supervision requirement is presumed to be met when services are performed on the hospital premises (i.e., certified as part of the hospital and part of the hospital campus); however, in all instances, it is required that the physician be present during the ascent and descent portions of each treatment.

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 7 OF: 15</b></p>
--	--

E. In order to satisfy the immediately available criteria, for HBO therapy performed in an outpatient hospital on-campus or off-campus provider based department, the physician (or qualified NPP) must be present in the office suite or at a location with a maximum of a five (5) minute response time to the chamber. For HBO performed in a physician office, the physician (or qualified NPP) must be present in the office suite.

VII. The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and thus these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

**DESCRIPTION:**

Hyperbaric oxygen therapy (HBOT) is a technique of delivering highly pressurized oxygen to the tissues. Two methods of administration are available.

In *systemic*, or *large chamber* hyperbaric oxygen, the patient is entirely enclosed in a pressure chamber and breathes near 100% oxygen intermittently at a pressure greater than one atmosphere (the pressure of O<sub>2</sub> at sea level). This technique relies on the systemic circulation to deliver highly oxygenated blood to the target site, typically a wound. In addition, systemic hyperbaric oxygen therapy can be used to treat systemic illness such as air or gas embolism, carbon monoxide poisoning, clostridial gas gangrene, etc. Treatment may be carried out either in a mono chamber (single person) chamber pressurized with near 100% O<sub>2</sub> or in a larger, multi-place (multi-person) chamber pressurized with compressed air, in which case the patient receives pure oxygen by mask, head hoods, or endotracheal tube.

*Topical* hyperbaric oxygen therapy describes a technique of delivering 100% O<sub>2</sub> directly to a wound site at a pressure slightly higher than atmospheric pressure. It is hypothesized that the high concentrations of oxygen diffuses directly into the wound to increase the local cellular oxygen tension, which in turn promotes wound healing. Topical HBOT devices consist of an appliance to enclose the wound area and a source of O<sub>2</sub>; conventional O<sub>2</sub> tanks may be used. The appliances may be disposable and may be used without supervision in the home by well-trained patients. Topical HBO<sub>2</sub> has been investigated as a treatment for skin ulcerations due to diabetes, venous stasis, post-surgical infection, gangrenous lesion, decubitus ulcers, amputations, skin graft or frostbite.

**RATIONALE:**

Hyperbaric oxygen therapy is a procedure; therefore it is not subject to U.S. Food and Drug Administration (FDA) regulation. The hyperbaric chambers used to administer the therapy do require and have received FDA approval.

HBOT for *autism spectrum disorders*. In 2009, a double-blind, randomized controlled study on the use of HBOT to treat children with autism was published and included 62 children, ages 2-7, diagnosed with an autistic disorder. The active group received hyperbaric treatment at 1.3 atmospheres (atm) and 24% oxygen in a hyperbaric chamber. The control group received a sham treatment consisting of 1.03 atm and ambient air (21% oxygen). Both groups received 40 sessions of active or sham treatment lasting 60 minutes each over a period of 4 weeks. After completion of the 4-week study, families with children in the control group were offered the active intervention. The outcomes were change compared to baseline after 4 weeks several scales: Aberrant Behavior Checklist (ABC); Autism Treatment Evaluation Checklist (ATEC); and Clinical Global Impression-Improvement (CGI). There was no significant differences between-group improvement on the ABC total score, any of the ABC subscales or on the ATEC total score. Compared to the control group, the treatment group had a significant improvement in the ATEC sensory/cognitive awareness subscale. On the physician-rated CGI total score, 30% of the children in the treatment group had a score of 1 (very much improved) or 2 (much improved) compared to 8% in the control group. On the parental-rated CGI total score, 30% of the children in the treatment group had a score of 1 or 2 compared to 15% in the control group. Among the parental-rated CGI subscales, significantly more children were rated as improved in the treatment group compared to control on 2 out of 18 subscales, receptive language and eye contact. A key limitation of the study was that the authors reported outcomes only directly after completion of the intervention. Whether there are any long-term effects is not known. Additional follow-up data cannot be obtained because members of the control group crossed over to the intervention after 4 weeks. Other

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 8 OF: 15</b></p>
--	--

limitations include lack of adjustment for multiple comparisons and unclear clinical significance of the statistically significant outcomes. Findings suggest improvements may be seen in some children with autism treated with HBOT, but when results are compared to a control group, no difference was found as measured by the three clinical instruments. Further research is needed to determine if HBOT is an effective treatment for autism. (Rossignol, et al., 2009)

In December 2009, the Undersea and Hyperbaric Medical Society issued a position paper stating they do not recommend routine treatment of autism with HBOT as there is very little evidence to support an effect of pressure alone or that oxygen has differing effects whether given by increasing ambient pressure or increasing the inspired fraction.

A 2016 Cochrane review by Xiong et al identified 1 RCT evaluating systemic HBOT for people with autism spectrum disorder who met reviewers' eligibility criteria and that trial did not find significantly improved outcomes with HBOT versus sham. The authors concluded that there is no evidence that hyperbaric oxygen therapy improves core symptoms and associated symptoms of ASD. Adding that it is important to note that adverse effects (minor-grade ear barotrauma events) can occur. Given the absence of evidence of effectiveness and the limited biological plausibility and possible adverse effects, the need for future RCTs of hyperbaric oxygen therapy must be carefully considered.

The use of HBOT for patients with *chronic refractory osteomyelitis* is supported by the Undersea and Hyperbaric Medical Society and the American College of Hyperbaric Medicine. Although no randomized clinical trials examining the effects of HBOT on chronic refractory osteomyelitis have been identified the substantial majority of available human case series and non-randomized prospective trials suggest that the addition of HBOT to routine surgical and antibiotic management in previously refractory osteomyelitis is safe and improves the ultimate rate of infection resolution.

*HBOT for Idiopathic Sudden Sensorineural Hearing Loss:* In 2015, an evidence-based literature review was reported that addresses the controversies in the management of sudden sensorineural hearing loss and proposes a treatment algorithm based on the highest quality evidence. The authors concluded if the hearing loss is idiopathic in nature patients may be offered a course of oral steroid. If systemic steroids are contraindicated and/or there is no improvement with initial oral therapy, intratympanic steroids as either primary or salvage therapy may be considered. They stated the cost, limited availability and lack of strong evidence for HBOT makes it impractical at present. (Lawrence, et al. 2015). A Cochrane review of RCTs had mixed findings. Some outcomes (ie, improvement in hearing of all frequencies, >25% return of hearing) were better with HBOT than with a control intervention, but more than 50% return of hearing did not differ significantly between groups. The RCTs had methodologic limitations. The evidence is insufficient to determine the effects of the technology on health outcomes and is considered investigational for idiopathic sudden sensorineural hearing loss. The early implementation of HBOT in sensorineural hearing loss may lead to full recovery of hearing. The critical first 48 hours to initialize HBO treatment for maximum effectiveness is a limiting factor for the successful outcomes of this treatment. The *Undersea and Hyperbaric Medical Society* has not listed this illness for HBO therapy so far.

*HBOT for radiation necrosis and osteoradionecrosis.* Given the limited number of options available to patients with these late effects of radiation therapy, results of cohort studies as well as randomized trials were used in evaluating clinical evidence. A retrospective case series of 65 patients with radiation enteritis/proctitis and 94 patients with cystitis were reported from one institution. Response was better in patients receiving 30 or more total treatments compared with fewer treatments. A Cochrane Review of randomized trials concluded that available small trials suggest that for people with late radiation tissue injury affecting the head, neck, anus and rectum, HBOT is associated with improved outcomes. HBOT also appears to reduce the change of osteoradionecrosis following tooth extraction in an irradiated field.

Published clinical trials have not provided evidence to support the efficacy and safety of hyperbaric oxygen therapy over current treatment options for the indications listed as investigational in this policy.



<b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b>  <b>POLICY NUMBER: 2.01.07</b> <b>CATEGORY: Technology Assessment</b>	<b>EFFECTIVE DATE: 11/19/99</b> <b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b>  <b>PAGE: 9 OF: 15</b>
---	---

**CODES:**      Number                      Description

*Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*

CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.

Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.

Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).

**CPT:**            99183                      Physician or other qualified health care professional attendance and supervision of hyperbaric oxygen therapy, per session

*Copyright © 2018 American Medical Association, Chicago, IL*

**HCPCS:**        A4575 (E/I)              Topical hyperbaric oxygen chamber, disposable  
E0446 (E/I)              Topical oxygen delivery system, not otherwise specified, includes all supplies and accessories  
G0277                      Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval

**ICD10:**        **Medically Appropriate diagnosis codes per Policy Statement IIA:**

A18.01                      Tuberculosis of spine  
A18.03                      Tuberculosis of other bones  
A42.0-A42.2              Actinomycosis (code range)  
A42.81-A42.89            Other forms of actinomycosis (code range)  
A42.9                      Actinomycosis, unspecified  
A43.0-A43.9              Nocardiosis (code range)  
A48.0                      Gas gangrene  
A50.01-A50.09            Early congenital syphilis, symptomatic (code range)  
A52.77                      Syphilis of bone and joint  
B36.0-B36.9              Other superficial mycoses (code range)  
B47.1-B47.9              Mycetoma (code range)  
B48.3                      Geotrichosis  
B48.8                      Other specified mycoses  
B49                      Unspecified mycosis  
D62                      Acute posthemorrhagic anemia  
E08.52                      Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene  
E09.52                      Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene  
E10.52                      Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 10 OF: 15</b></p>
--	---

E10.618-E10.69	Type 1 diabetes mellitus with other specified complications (code range)
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene
E11-618-E11.69	Type 2 diabetes mellitus with other specified complication
E13.52-E13.69	Other specified diabetes mellitus (code range)
G93.6	Cerebral edema
H05.021-H05.029	Osteomyelitis of orbit (code range)
I70.361-I70.769	Atherosclerosis of bypass graft(s) of the extremities with gangrene (code range)
I70.461-I70.469	Atherosclerosis of autologous vein bypass graft(s) of the extremities with gangrene (code range)
I73.01	Raynaud's syndrome with gangrene
I96	Gangrene, not elsewhere classified
K12.2	Cellulitis and abscess of mouth
L02.01-L02.91	Cutaneous abscess (code range)
L03.111-L03.119	Cellulitis (code range)
L03.121-L03.129	Acute lymphangitis (code range)
L03.211-L03.91	Cellulitis and acute lymphangitis (code range)
L08.1	Erythrasma
L59.9	Disorder of the skin and subcutaneous tissue related to radiation, unspecified
L98.3	Eosinophilic cellulitis (Wells)
M27.2	Inflammatory conditions of jaws
M27.8	Other specified diseases of jaws
M46.20-M46.28	Osteomyelitis of vertebra (code range)
M46.30-M46.39	Infection of intervertebral disc (pyogenic) (code range)
M86.00-M86.09	Acute hematogenous osteomyelitis (code range)
M86.10-M86.19	Other acute osteomyelitis (code range)
M86.20-M86.29	Subacute osteomyelitis (code range)
M86.30-M86.69	Chronic osteomyelitis (code range)
M86.8x0-M86.9	Other and unspecified osteomyelitis (code range)
M90.80-M90.89	Osteopathy in diseases classified elsewhere (code range)
P11.0	Cerebral edema due to birth injury
S06.1x0A- S06.1x9A	Traumatic cerebral edema (code range)
S07.0xxA, S17.9xxA,	Crushing injury (code range)

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 11 OF: 15</b></p>
--	---

T57.3x1A- T57.3x4A	Toxic effect of hydrogen cyanide (code range)
T58.01xA- T58.94xA	Toxic effect of carbon monoxide (code range)
T65.0x1A- T65.0x4A	Toxic effect of cyanides (code range)
T66.xxxA	Radiation sickness, unspecified, initial encounter
T70.3xxA	Caisson disease (decompression sickness), initial encounter
T79.0xxA	Air embolism (traumatic), initial encounter
T86.820-T86.822	Complications of skin graft (allograft) (autograft) (code range)
T86.828-T86.829	Other and unspecified complications of skin graft (allograft) (autograft) (code range)

ICD10: Investigational diagnosis codes per Policy Statement IIB (Codes may not be all inclusive):

G12.21	Amyotrophic lateral sclerosis
F84.0	Autistic disorder
G51.0	Bell's palsy
T63.333A-T63.332S	Toxic effect of venom of brown recluse spider (code range)
T53.0X1A-T53.0X2S	Toxic effects of carbon tetrachloride (code range)

## **REFERENCES:**

Agency for Healthcare Research and Quality; Saha S, et al. Pressure ulcer treatment strategies: comparative effectiveness. Comparative Effectiveness Review No. 90. AHRQ Publication No. 13-EHC003-EF. Rockville, MD; 2013 May [http://www.effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productid=1492] accessed 2/2/18.

\*American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Critical Issues in the Management of Adult Patients Presenting to the Emergency Department with Carbon Monoxide Poisoning. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with acute carbon monoxide poisoning. Ann Emerg Med 2008 Feb;51(2):138-52.

American College of Hyperbaric Medicine. Frequently asked questions. What are the approved indications for hyperbaric oxygen therapy? [http://www.achm.org/faq/] accessed 2/6/18.

Annane D, et al. Hyperbaric oxygen therapy for acute domestic carbon monoxide poisoning: two randomized controlled trials. Intensive Care Med 2011 Mar;37(3):486-92.

Baynosa RC and Zamboni WA. The effect of hyperbaric oxygen on compromised grafts and flaps. Undersea Hyperb Med 2012 Jul-Aug;39(4):857-65.

Bennett M, et al. Hyperbaric oxygen for acute coronary syndrome. Cochrane Database Syst Rev 2015, Issue 7. Art. No CD004818.

Bennett MH, et al. Hyperbaric oxygen therapy for acute ischemic stroke. Cochrane Database Syst Rev 2014 Nov 12;11:CD004954.

\*Bennett M, et al. Hyperbaric oxygen therapy for the adjunctive treatment of traumatic brain injury. Cochrane Database Syst Rev 2012 Dec 12;(12):CD004609.

\*Bennett M, et al. Hyperbaric oxygen therapy for delayed onset muscle soreness and closed soft tissue injury.

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 12 OF: 15</b></p>
--	---

Cochrane Database Syst Rev 2005 Oct 19;(4):CD004713.

Bennett MH, et al. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. Cochrane Database Syst Rev. 2012 Oct 17;10:CD004739.

Bennett MH, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev. 2012 May 16;5:CD005005.

\*Bennett MH, et al. Hyperbaric oxygen therapy for multiple sclerosis. Cochrane Database Syst Rev 2004, Issue 1. Art. No.: CD003057.

Bennett MH, et al. Hyperbaric oxygen therapy for promoting fracture healing and treating fracture non-union. Cochrane Database Syst Rev. 2012 Nov 14;11:CD004712.

\*Bennett M, et al. Hyperbaric oxygen for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 2012 Apr 18;4:CD005007.

\*Bennett MH, et al. Normobaric and hyperbaric oxygen therapy for migraine and cluster headache. Cochrane Database of Systematic Reviews 2015, Issue 12. Art. No.: CD005219.

Bennett MH. Randomized controlled trials in diving and hyperbaric medicine. Undersea Hyperb Med 2013 Sep-Oct;40(5):419-38.

\*Bennett M, et al. UHMS position paper. The treatment of autism spectrum disorder with hyperbaric oxygen therapy. 2009 Dec 5 [[https://www.uhms.org/images/Position-Statements/autism\\_position\\_paper.pdf](https://www.uhms.org/images/Position-Statements/autism_position_paper.pdf)] accessed 2/6/18.

BlueCross BlueShield Association. Hyperbaric oxygen therapy. Medical Policy Reference Manual Policy #2.01.04 2018 Jan 11.

\*Boudreau R, et al. Hyperbaric oxygen therapy for difficult wound healing: systematic review of clinical effectiveness and cost-effectiveness, Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010 Jun [[http://www.cadth.ca/media/pdf/M0016\\_HBOT\\_L3\\_e.pdf](http://www.cadth.ca/media/pdf/M0016_HBOT_L3_e.pdf)] accessed 2/6/18.

Buckley NA, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database of Systematic Reviews 2011, Issue 4. Art. No.: CD002041.

\*Canadian Agency for Drugs and Technologies in Health. Hyperbaric oxygen therapy for autism: a review of the clinical and cost-effectiveness. 2009 Nov 19 [[http://www.cadth.ca/media/pdf/L0141\\_Hyperbaric\\_Oxygen\\_final.pdf](http://www.cadth.ca/media/pdf/L0141_Hyperbaric_Oxygen_final.pdf)] accessed 2/6/18.

Churchill S, et al. A prospective trial of hyperbaric oxygen for chronic sequelae after brain injury (HYBOBI). Undersea Hyperb Med 2013 Mar-Apr;40(2):165-93.

Dauwe PB, et al. Does hyperbaric oxygen therapy work in facilitating acute wound healing: a systematic review. Plast Reconstr Surg 2014 Feb;133(2):208e-15e.

de Smet GHJ, Kroese LF, Menon AG, et al. Oxygen therapies and their effects on wound healing. Wound Repair Regen. Aug 2017;25(4):591-608.

Dulai PS, et al. Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther 2014 Jun;39(11):1266-75.

Eskes A, et al. Hyperbaric oxygen therapy for treating acute surgical and traumatic wounds. Cochrane Database Syst Rev 2013 Dec 16;(12): CD008059.

\*Eskes AM, et al. Hyperbaric oxygen therapy: solution for difficult to heal acute wounds? Systematic review. World J Surg 2011 Mar;35(3):535-42.

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 13 OF: 15</b></p>
--	---

- \*Esposito M, et al. Interventions for replacing missing teeth: hyperbaric oxygen therapy for irradiated patients who require dental implants. *Cochrane Database Syst Rev* 2013 Sep 30;(9):CD003603.
- \*Feldmeier JJ and Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen prevention and treatment of delayed injuries: an evidence-based approach. *Undersea Hyperbaric Med* 2002;29(1):4-29.
- Fedorko L, et al. Hyperbaric oxygen therapy does not reduce indications for amputation in patients with diabetes with nonhealing ulcers of the lower limb: a prospective, double-blind, randomized controlled clinical trial. *Diabetes Care* 2016 Jan 6. pii: dc152001 [Epub ahead of print].
- Feldmeier JJ. Hyperbaric oxygen therapy and delayed radiation injuries (soft tissue and bony necrosis): 2012 update. *Undersea Hyperb Med* 2012 Nov-Dec;39(6):1121-39.
- Holland NJ, et al. Hyperbaric oxygen therapy for Bell's palsy. *Cochrane Database Syst Rev*. 2012 Feb 15;2:CD007288.
- Holland S, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. *Neurology* 2012 Apr 24;78(17):1346-53.
- Hosokawa S, et al. Prognostic factors for idiopathic sudden sensorineural hearing loss treated with hyperbaric oxygen therapy and intravenous steroids. *J Laryngol Otol*. 2017 Jan;131(1):77-82. Epub 2016 Dec 5.
- Hu SC, et al. High-glucose environment disturbs the physiologic functions of keratinocytes: Focusing on diabetic wound healing. *J Dermatol Sci*. 2016 Nov;84(2):121-127.
- Hu SL, et al. Hyperbaric oxygen therapy and preconditioning for ischemic and hemorrhagic stroke. *Med Gas Res*. 2016 Dec 30;6(4):232-236.
- Hu Q, et al. Hyperbaric oxygen therapy for traumatic brain injury: bench-to-bedside. *Med Gas Res*. 2016 Jul 11;6(2):102-110.
- Huang ET, et al; UHMS CPG Oversight Committee. A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers. *Undersea Hyperb Med* 2015 May-Jun;42(3):205-47.
- Huang SM, et al. High-glucose environment induced intracellular O-GlcNAc glycosylation and reduced galectin-7 expression in keratinocytes: Implications on impaired diabetic wound healing. *J Dermatol Sci*. 2017 Aug;87(2):168-175.
- \*Juurink DN, et al. Hyperbaric oxygen for carbon monoxide poisoning. *Cochrane Database Syst Rev* 2005 Jan 25;(1):CD002041.
- Khan AA, et al; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015 Jan;30(1):3-23.
- \*Kot J and Mathieu D. Controversial issues in hyperbaric oxygen therapy: a European Committee for Hyperbaric Medicine Workshop. *Diving Hyperb Med* 2011 Jun;41(2):101-4.
- Kranke P et al. Hyperbaric oxygen therapy for chronic wounds. *Cochrane Database Syst Rev* 2015;6:CD004123.
- Lawrence R and Thevasagayam R. Controversies in the management of sudden sensorineural hearing loss: an evidence-based review. *Clin Otolaryngol* 2015 Jun;40(3):176-82.
- Levett D, et al. Adjunctive hyperbaric oxygen for necrotizing fasciitis. *Cochrane Database of Systematic Reviews* 2015, Issue 1. Art. No.: CD007937.
- Liu R, et al. Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers. *Mayo Clin Proc* 2013 Feb;88(2):166-75.

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 14 OF: 15</b></p>
--	---

Löndahl M, et al. Hyperbaric oxygen therapy improves health-related quality of life in patients with diabetes and chronic foot ulcer. Diabet Med 2011 Feb;28(2):186-90.

Löndahl M, et al. What is the role of hyperbaric oxygen in the management of diabetic foot disease? Curr Diab Rep 2011 Aug;11(4):285-93.

Marx RE. Osteoradionecrosis of the Jaws: Review and Update. Assistant Chairman of Oral and Maxillofacial Surgery, Wilford Hall USAF Medical Center, San Antonio, TX. HBO Review, Vol. 5, No. 2.

Mathieu D, Marroni A, Kot J. Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. Diving Hyperb Med. Mar 2017;47(1):24-32.

\*Michalski D, et al. Use of normobaric and hyperbaric oxygen in acute focal cerebral ischemia - a preclinical and clinical review. Acta Neurol Scand 2011 Feb;123(2):85-97.

Moffat AD, et al. Glycosylated hemoglobin and hyperbaric oxygen coverage denials. Undersea Hyperb Med. 2015 May-Jun;42(3):197-204.

Moon RE. Hyperbaric oxygen treatment for decompression sickness. Undersea Hyperb Med 2014 Mar-Apr;41(2):151-7.

Murphy-Lavoie H, et al. Hyperbaric oxygen therapy for idiopathic sudden sensorineural hearing loss. Undersea Hyperb Med 2012 May-Jun;39(3):777-92.

Mutluoglu M, et al. Poorly designed research does not help clarify the role of hyperbaric oxygen in the treatment of chronic diabetic foot ulcers. Diving Hyperb Med. 2016 Sep;46(3):133-134.

Olex-Zarchta D. Successful treatment of sudden sensorineural hearing loss by means of pharmacotherapy combined with early hyperbaric oxygen therapy: Case report. Medicine (Baltimore). 2017 Dec;96(51):e9397.

O'Reilly D, et al. A prospective, double-blind, randomized, controlled clinical trial comparing standard wound care with adjunctive hyperbaric oxygen therapy (HBOT) to standard wound care only for the treatment of chronic, non-healing ulcers of the lower limb in patients with diabetes mellitus: a study protocol. Trials 2011 Mar 7;12:69.

Payne H, et al. Chemical- and radiation-induced haemorrhagic cystitis: current treatments and challenges. BJU Int 2013 Nov;112(7):885-97.

Peterson C et al. Delayed Presentation of Cerebral Air Embolism from a Left Atrial-Esophageal Fistula: A Case Report and Review of the Literature. Cureus. 2017 Nov 15;9(11):e1850.

Phillips JS and Jones SE. Hyperbaric oxygen as an adjuvant treatment for malignant otitis externa. Cochrane Database Syst Rev 2013 May 31;5:CD004617.

\*Piantadosi CA. Perspective: carbon monoxide poisoning. NEJM 2002 Oct 3; 347(14):1054-5.

Ravi P, Vaishnavi D, Gnanam A, et al. The role of hyperbaric oxygen therapy in the prevention and management of radiation-induced complications of the head and neck - a systematic review of literature. J Stomatol Oral Maxillofac Surg. Dec 2017;118(6):359-362.

Sadri RA, Cooper JS. Hyperbaric, complications. NCBI Bookshelf 2017; [https://www.ncbi.nlm.nih.gov/books/NBK459191/] accessed 2/6/18.

Sayadi LR et al. Topical oxygen therapy & micro/nanobubbles: a new modality for tissue oxygen delivery. Int Wound J. 2018 Jan 5. doi: 10.1111/iwj.12873. [Epub ahead of print]

Shakya S, et al. Hyperglycemia-Induced Changes in Hyaluronan Contribute to Impaired Skin Wound Healing in Diabetes: Review and Perspective. Int J Cell Biol. 2015;2015:701738.

<p><b>SUBJECT: HYPERBARIC OXYGEN THERAPY (HBOT)</b></p> <p><b>POLICY NUMBER: 2.01.07</b></p> <p><b>CATEGORY: Technology Assessment</b></p>	<p><b>EFFECTIVE DATE: 11/19/99</b></p> <p><b>REVISED DATE: 04/17/02, 04/24/03, 05/19/04, 07/21/05, 09/21/06, 07/19/07, 06/19/08, 09/18/08, 09/17/09, 02/17/11, 04/19/12, 03/21/13, 03/20/14, 03/19/15, 03/17/16, 04/20/17, 05/17/18</b></p> <p><b>PAGE: 15 OF: 15</b></p>
--	---

Stachler RJ, et al; American Academy of Otolaryngology-Head and Neck Surgery. Clinical practice guideline: sudden hearing loss. Otolaryngol Head Neck Surg 2012 Mar;146(3 Suppl):S1-35.

Stoekenbroek RM, et al. Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review. Eur J Vasc Endovasc Surg 2014 Jun;47(6):647-55.

\*Tang X, et al. The effect of hyperbaric oxygen on clinical outcome of patients after resection of meningiomas with conspicuous peritumoral brain edema. Undersea Hyperb Med 2011 Mar-Apr;38(2):109-15.

\*Villanueva E, et al. Hyperbaric oxygen therapy for thermal burns. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No.: CD004727.

\*Weaver LK, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. NEJM 2002 Oct 3;347(14):1057-67.

Weaver LK, et al. Glycosylated hemoglobin and hyperbaric oxygen coverage denials UHM 2015, Vol. 42, No. 3

Xiang W, et al. Combined application of dexamethasone and hyperbaric oxygen therapy yields better efficacy for patients with delayed encephalopathy after acute carbon monoxide poisoning. Drug Des Devel Ther. 2017 Feb 23;11:513-519.

Xiao Y, et al. Hyperbaric oxygen therapy for vascular dementia. Cochrane Database Syst Rev. 2012 Jul 11;7:CD009425.

Xiong T, Chen H, Luo R, et al. Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). Cochrane Database Syst Rev. Oct 13 2016;10:CD010922.

**KEY WORDS:**

HBOT, Systemic hyperbaric oxygen therapy, Topical hyperbaric oxygen pressurization, Topical hyperbaric oxygen therapy, Topical oxygen wound therapy, TOWT.

## CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

There is currently a National Coverage Determination (NCD)

Please refer to the following websites for Medicare Members:

**NCD:**

<https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=12&ncdver=3&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Entire+State&KeyWord=hyperbaric&KeyWordLookUp=Title&KeyWordSearchType=And&articleId=52174&ver=24&ContrId=298&ContrVer=1&bc=gAAAABAAAAAAAAAA%3d%3d&>